Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PM8002 and PM1009 in Advanced Hepatocellular Carcinoma
NCT06584071Phase 2Not yet recruiting
- Sponsor
- Biotheus
- Start
- Dec 2024
- Primary completion
- Oct 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
01
Overview
A Phase 2 trial of pumitamig, PM1009 in hepatocellular carcinoma (HCC), sponsored by Biotheus. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
pumitamigPM1009
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06584071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06584071.